Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about POINT Biopharma Global Inc.
POINT Biopharma Global Inc. News
POINT Biopharma Global Inc. Quantitative Score
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
POINT Biopharma Global Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
POINT Biopharma Global Inc. Financials
Table Compare
Compare PNT metrics with: | |||
|---|---|---|---|
Earnings & Growth | PNT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PNT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PNT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PNT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
POINT Biopharma Global Inc. Income
POINT Biopharma Global Inc. Balance Sheet
POINT Biopharma Global Inc. Cash Flow
POINT Biopharma Global Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
POINT Biopharma Global Inc. Executives
| Name | Role |
|---|---|
| Dr. Joe A. McCann Ph.D. | Chief Executive Officer & Director |
| Mr. Allan Charles Silber | Executive Chairman |
| Ms. Jessica D. Jensen M.P.H., MPH | Executive Vice President of Clinical Devel. |
| Dr. Neil E. Fleshner FRCSC, M.D., M.PH | Chief Medical Officer & Director |
| Mr. Todd Hockemeyer B.E. | Executive Vice President of US Manufacturing Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Joe A. McCann Ph.D. | Chief Executive Officer & Director | 1978 | 1.06M | |
| Mr. Allan Charles Silber | Executive Chairman | Male | 1950 | 1.02M |
| Ms. Jessica D. Jensen M.P.H., MPH | Executive Vice President of Clinical Devel. | Female | 1981 | 816.17K |
| Dr. Neil E. Fleshner FRCSC, M.D., M.PH | Chief Medical Officer & Director | 1964 | 318.49K | |
| Mr. Todd Hockemeyer B.E. | Executive Vice President of US Manufacturing Operations | Male | -- |
POINT Biopharma Global Inc. Insider Trades
| Date | 26 Dec |
| Name | GOODMAN JONATHAN R. |
| Role | Director |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 41872 |
| Date | 27 Dec |
| Name | GOODMAN JONATHAN R. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 35872 |
| Date | 27 Dec |
| Name | GOODMAN JONATHAN R. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 25000 |
| Date | 27 Dec |
| Name | GOODMAN JONATHAN R. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 25614 |
| Date | 27 Dec |
| Name | GOODMAN JONATHAN R. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 44749 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 26 Dec | GOODMAN JONATHAN R. | Director | Disposed | U-Tender | 41872 |
| 27 Dec | GOODMAN JONATHAN R. | Director | Disposed | D-Return | 35872 |
| 27 Dec | GOODMAN JONATHAN R. | Director | Disposed | D-Return | 25000 |
| 27 Dec | GOODMAN JONATHAN R. | Director | Disposed | D-Return | 25614 |
| 27 Dec | GOODMAN JONATHAN R. | Director | Disposed | D-Return | 44749 |